
Sars Cov Peptide
Human IgG antibody Laboratories manufactures the sars cov peptide reagents distributed by Genprice. The Sars Cov Peptide reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Peptide. Other Sars products are available in stock. Specificity: Sars Category: Cov Group: Peptide
SARS-CoV-2 (COVID-19) ORF9b Peptide |
|||
9191P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF9b Peptide |
SARS-CoV-2 (COVID-19) ORF3a Peptide |
|||
9275P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF3a Peptide |
SARS-CoV-2 (COVID-19) ORF3b Peptide |
|||
9277P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide |
SARS-CoV-2 (COVID-19) ORF3b Peptide |
|||
9279P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide |
SARS-CoV-2 (COVID-19) ORF3b Peptide |
|||
9281P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide |
SARS-CoV-2 (COVID-19) ORF7a Peptide |
|||
9283P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF7a Peptide |
SARS-CoV-2 (COVID-19) ORF7a Peptide |
|||
9285P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF7a Peptide |
SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
9287P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide |
SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
9289P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide |
SARS-CoV-2 (COVID-19) ORF9c Peptide |
|||
9291P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF9c Peptide |
SARS-CoV-2 (COVID-19) ORF10 Peptide |
|||
9293P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF10 Peptide |
SARS-CoV Spike Antibody |
|||
3219-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3219-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3221-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3221-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3223-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3223-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |